Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor.

Abstract

Trandolapril is a newly developed angiotensin-converting enzyme (ACE) inhibitor that is rapidly hydrolyzed mainly in the liver to its biologically active metabolite trandolaprilat. The time to reach peak plasma concentrations of trandolaprilat is about 6 hours; the effective plasma half-life of accumulation at steady state is 24 hours. The active metabolite… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.